ABBV-383
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for ABBV-383, covering 2025-08-08 to 2026-03-27. Get the full timeline:
Most recent: Clinical Trial Update: Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]